NSG 6001 Advanced Pharmacology | Week 2 Quiz 2026/2027 Edition
NSG 6001: ADVANCED PHARMACOLOGY - WEEK 2 QUIZ
Advanced Practice Nursing Education | Pharmacokinetics, Pharmacodynamics, Drug Interactions,
and Prescribing Principles
Complete Quiz with 25 Verified Questions and 100% Correct Answers
Aligned with 2026/2027 course objectives and current advanced pharmacology standards
Sections 1-4 | 25 Items | Cognitive Levels: 30% Recall, 50% Application, 20% Analysis | 70% Scenario-Based, 30% Direct Recall
SECTION 1: PHARMACOKINETICS
Absorption, Distribution, Metabolism, and Excretion | Questions 1-8
Q1: A nurse practitioner is selecting a regimen for a 62-year-old patient with chronic stable angina who experiences
predictable exertional episodes. Sublingual nitroglycerin is prescribed for acute attacks instead of an oral tablet
formulation. The primary pharmacokinetic advantage of the sublingual route for this indication is that it:
A. Produces slower, more gradual absorption that prolongs the antianginal effect
B. Delivers drug directly into the systemic circulation via the superior vena cava, bypassing hepatic first-pass
metabolism and markedly increasing bioavailability [CORRECT]
C. Increases reversible binding to plasma albumin, which extends the elimination half-life
D. Avoids glomerular filtration of the drug, thereby reducing the risk of nephrotoxicity
Correct Answer: B
Rationale: Sublingual nitroglycerin is absorbed across the oral mucosa into the superior vena cava and reaches the
systemic circulation before ever passing through the portal vein, so the extensive hepatic CYP-mediated first-pass
metabolism that destroys most of an oral dose is bypassed. Oral nitroglycerin bioavailability is extremely low, which is
why maintenance therapy uses longer-acting oral or transdermal nitrates rather than immediate-release tablets for
acute episodes. Option A is incorrect because sublingual absorption is rapid, not slow, and rapid onset is exactly what
an acute attack requires. Options C and D describe protein binding and renal elimination processes that are intrinsic
drug properties and do not change with the route of administration.
1
, NSG 6001 Advanced Pharmacology | Week 2 Quiz 2026/2027 Edition
Q2: A 57-year-old patient with advanced cirrhosis and hypoalbuminemia (serum albumin 2.1 g/dL) has been taking
phenytoin, which is approximately 90 percent protein bound, for a seizure disorder. When interpreting the therapeutic
drug monitoring results, the APRN should recognize that:
A. Total serum phenytoin concentrations will be falsely elevated because of enhanced protein binding
B. Hypoalbuminemia increases the bound fraction, so the daily dose should be increased to compensate
C. Free phenytoin concentrations fall below the therapeutic range, so the total dose should be doubled
D. The unbound fraction is increased, so total levels may appear therapeutic despite clinical toxicity; free
(unbound) phenytoin levels should be monitored [CORRECT]
Correct Answer: D
Rationale: Only the unbound fraction of a drug leaves the vascular compartment, diffuses into tissue, and produces
pharmacologic effect. With low albumin, fewer binding sites are available, so the free fraction of this highly bound
drug rises even though the measured total concentration may fall within the usual therapeutic range. Monitoring free
phenytoin levels prevents the dangerous error of escalating the dose based on misleading total concentrations, an
especially important safeguard in cirrhosis where hepatic CYP-mediated clearance may also be impaired. Options A,
B, and C all reverse the physiology, because protein binding is decreased rather than increased in hypoalbuminemia.
Q3: A patient with mild Alzheimer disease starts donepezil, which has a half-life of approximately 70 hours. When
counseling the patient and family about the time course of therapy, the APRN should explain that the full steady-state
plasma concentration, and therefore maximal clinical effect, will require approximately:
A. 70 hours, which is a single half-life
B. 3 to 4 days of uninterrupted dosing
C. 12 to 14 days, because steady state is reached after about 4 to 5 half-lives [CORRECT]
D. 6 to 8 weeks, because donepezil accumulates indefinitely
Correct Answer: C
Rationale: Regardless of dose size or route, steady state is achieved after approximately 4 to 5 half-lives; for
donepezil with a 70-hour half-life this equals roughly 12 to 14 days of consistent dosing. Administering a loading dose
can place plasma concentrations within the therapeutic range sooner, but it does not shorten the time to true steady
state. Option A describes only one half-life, at which point half of the eventual accumulation has occurred, and option
B substantially underestimates the interval. Option D overestimates the timeline and mischaracterizes donepezil
accumulation, which plateaus at steady state rather than continuing indefinitely.
2
NSG 6001: ADVANCED PHARMACOLOGY - WEEK 2 QUIZ
Advanced Practice Nursing Education | Pharmacokinetics, Pharmacodynamics, Drug Interactions,
and Prescribing Principles
Complete Quiz with 25 Verified Questions and 100% Correct Answers
Aligned with 2026/2027 course objectives and current advanced pharmacology standards
Sections 1-4 | 25 Items | Cognitive Levels: 30% Recall, 50% Application, 20% Analysis | 70% Scenario-Based, 30% Direct Recall
SECTION 1: PHARMACOKINETICS
Absorption, Distribution, Metabolism, and Excretion | Questions 1-8
Q1: A nurse practitioner is selecting a regimen for a 62-year-old patient with chronic stable angina who experiences
predictable exertional episodes. Sublingual nitroglycerin is prescribed for acute attacks instead of an oral tablet
formulation. The primary pharmacokinetic advantage of the sublingual route for this indication is that it:
A. Produces slower, more gradual absorption that prolongs the antianginal effect
B. Delivers drug directly into the systemic circulation via the superior vena cava, bypassing hepatic first-pass
metabolism and markedly increasing bioavailability [CORRECT]
C. Increases reversible binding to plasma albumin, which extends the elimination half-life
D. Avoids glomerular filtration of the drug, thereby reducing the risk of nephrotoxicity
Correct Answer: B
Rationale: Sublingual nitroglycerin is absorbed across the oral mucosa into the superior vena cava and reaches the
systemic circulation before ever passing through the portal vein, so the extensive hepatic CYP-mediated first-pass
metabolism that destroys most of an oral dose is bypassed. Oral nitroglycerin bioavailability is extremely low, which is
why maintenance therapy uses longer-acting oral or transdermal nitrates rather than immediate-release tablets for
acute episodes. Option A is incorrect because sublingual absorption is rapid, not slow, and rapid onset is exactly what
an acute attack requires. Options C and D describe protein binding and renal elimination processes that are intrinsic
drug properties and do not change with the route of administration.
1
, NSG 6001 Advanced Pharmacology | Week 2 Quiz 2026/2027 Edition
Q2: A 57-year-old patient with advanced cirrhosis and hypoalbuminemia (serum albumin 2.1 g/dL) has been taking
phenytoin, which is approximately 90 percent protein bound, for a seizure disorder. When interpreting the therapeutic
drug monitoring results, the APRN should recognize that:
A. Total serum phenytoin concentrations will be falsely elevated because of enhanced protein binding
B. Hypoalbuminemia increases the bound fraction, so the daily dose should be increased to compensate
C. Free phenytoin concentrations fall below the therapeutic range, so the total dose should be doubled
D. The unbound fraction is increased, so total levels may appear therapeutic despite clinical toxicity; free
(unbound) phenytoin levels should be monitored [CORRECT]
Correct Answer: D
Rationale: Only the unbound fraction of a drug leaves the vascular compartment, diffuses into tissue, and produces
pharmacologic effect. With low albumin, fewer binding sites are available, so the free fraction of this highly bound
drug rises even though the measured total concentration may fall within the usual therapeutic range. Monitoring free
phenytoin levels prevents the dangerous error of escalating the dose based on misleading total concentrations, an
especially important safeguard in cirrhosis where hepatic CYP-mediated clearance may also be impaired. Options A,
B, and C all reverse the physiology, because protein binding is decreased rather than increased in hypoalbuminemia.
Q3: A patient with mild Alzheimer disease starts donepezil, which has a half-life of approximately 70 hours. When
counseling the patient and family about the time course of therapy, the APRN should explain that the full steady-state
plasma concentration, and therefore maximal clinical effect, will require approximately:
A. 70 hours, which is a single half-life
B. 3 to 4 days of uninterrupted dosing
C. 12 to 14 days, because steady state is reached after about 4 to 5 half-lives [CORRECT]
D. 6 to 8 weeks, because donepezil accumulates indefinitely
Correct Answer: C
Rationale: Regardless of dose size or route, steady state is achieved after approximately 4 to 5 half-lives; for
donepezil with a 70-hour half-life this equals roughly 12 to 14 days of consistent dosing. Administering a loading dose
can place plasma concentrations within the therapeutic range sooner, but it does not shorten the time to true steady
state. Option A describes only one half-life, at which point half of the eventual accumulation has occurred, and option
B substantially underestimates the interval. Option D overestimates the timeline and mischaracterizes donepezil
accumulation, which plateaus at steady state rather than continuing indefinitely.
2
